✨ Free AI Report
Lyell Immunopharma: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Lyell Immunopharma
Company Research

Lyell Immunopharma: Business Overview, Financials & Competitive Analysis

Lyell Immunopharma is a clinical-stage cell therapy company developing chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company represents a cr...

Analyst-debate audio for Lyell Immunopharma

AskCyborg analysts argue the bull and bear cases for Lyell Immunopharma across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Lyell targets the lucrative solid tumor CAR-T market with differentiated technology, but remains pre-commercial with near-term...

Read the full analyst-debate transcript →
Industry Biotechnology / Cell Therapy / CAR-T Immunotherapy
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Lyell Immunopharma Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Lyell Immunopharma Overview

Pro stress-test →

Lyell Immunopharma is a clinical-stage cell therapy company developing chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company represents a crucial advance in using cell therapy to treat approximately 90% of cancers that are solid tumors, which have proven difficult to treat with existing cell therapies.

Strategic Profile

Pro stress-test →

Lyell's product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. The company's lead clinical program, LYL314, is a next-generation autologous dual-targeting CD19/CD20 CAR T-cell product candidate under evaluation in a pivotal trial enrolling patients with relapsed and/or refractory large B-cell lymphoma.

Competitive Landscape

Pro stress-test →

Lyell competes in the CAR-T immunotherapy space against Arcellx, Aura Biosciences, ORIC Pharmaceuticals, Adaptimmune Therapeutics, and Allogene Therapeutics among approximately 53 competitors. The company differentiates through proprietary T-cell reprogramming technologies targeting solid tumors, a less competitive but higher-potential segment than hematologic malignancies.

Industry Context

Lyell Immunopharma operates in Biotechnology / Cell Therapy / CAR-T Immunotherapy.

Key facts

Founded: 2018 · Headquarters: South San Francisco, California · Employees: 300 · Revenue: $61K · Market cap: $469M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Lyell Immunopharma.

  • Lead program LYL314 advancing through pivotal development for large B-cell lymphoma with positive Phase 1/2 data
  • Strategic acquisition of ImmPACT Bio strengthened pipeline with dual-targeting CD19/CD20 CAR T-cell candidate
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Acquired global rights to CAR T-cell candidate for colorectal cancer from Innovative Cellular Therapeutics
  • August 2025Reported positive clinical data from LYL314 Phase 1/2 trial with high rates of durable complete responses
  • +1 moreTrack every material event for Lyell Immunopharma as it happens. Explore monitoring →
Get alerted when Lyell Immunopharma has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T TherapiesCAR-T cell therapy developer for hematologic and solid tumors→CAR-T TherapiesEngineered T-cell therapy platform for cancer→TIL TherapiesTumor-infiltrating lymphocyte cell therapy→Gene TherapyOff-the-shelf allogeneic CAR-T cell therapy→

Compare Lyell Immunopharma with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Lyell Immunopharma operates in Biotechnology / Cell Therapy / CAR-T Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Cell Therapy / CAR-T Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Lyell Immunopharma

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Lyell Immunopharma and its top competitor on Cyborg Score”
“What did Lyell Immunopharma do this quarter?”
“Is Lyell Immunopharma a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Lyell Immunopharma do?+
Lyell Immunopharma is a clinical-stage cell therapy company developing chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company represents a cr...
What is Lyell Immunopharma's Cyborg Score?+
Lyell Immunopharma has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Lyell Immunopharma's main competitors?+
Named competitors include CAR-T Therapies, CAR-T Therapies, TIL Therapies, Gene Therapy. The full competitive landscape is in the AskCyborg report.
How can I get the full Lyell Immunopharma research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Lyell Immunopharma research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Lyell Immunopharma over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score